Psychiatr. pro Praxi, 2001; 4: 165-168

Proarytmické účinky psychofarmak

MUDr. Tomáš Novotný1, prof. MUDr. Bořivoj Semrád CSc2
1 Urologická klinika 3. LF UK a FN KV v Praze
2 Interní kardiologická klinika FN a LF MU v Brně

Published: December 31, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novotný T, Semrád B. Proarytmické účinky psychofarmak. Psychiatr. praxi. 2001;2(4):165-168.

Psychofarmaka jsou léky s významným celospolečenským dopadem. Mezi vedlejší účinky jejich léčby však patří i náhlá úmrtí. Tento přehledný článek shrnuje nejnovější poznatky o tomto jevu - jeho výskytu, možných mechanizmech, uvádí preparáty, u nichž byl popsán. Upozorňuje na nejvýznamnější rizikové faktory a na závěr nabízí možnosti prevence této fatální komplikace u, v dobré víře, léčených pacientů.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abbott, GW., Sesti, F., Splawski, I., et al. (1999) MIRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhyhtmia. Cell 97: 175-187. Go to original source... Go to PubMed...
    2. Appleby, L., Thomas, S., Ferrier, A., et al. (2000) Sudden unexplained death in psychiatric in-patients. Br J Psychiatry, 176: 405-406. Go to original source... Go to PubMed...
    3. Beasely, CM., Tollefson, GD., Tran, PV. (1997): Safety of olanzapine. J Clin Psychiatry 58 (suppl 10): 13-17.
    4. Committee for Proprietary Medicinal Products (CPMP). (1997) Points to consider: The assessment of the potential for QT interval prolongation by non cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products, December.
    5. Cutler, NR., Sramek, J. (2000): Atypical antipsychotics and QT prolongation: A class effect. Curr Op CPNS Invest Drugs 2: 52-57.
    6. Daniel, DG., Zimbroff, DL., Potkin, SG., Reeves, KR., Harrigan, EP., Lakshminarayanan, M. (1999): Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychophyrmacology 1999, 20: 491-505. Go to original source... Go to PubMed...
    7. Chouinard, G., Jones, B., Remington, G., et al. (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25-40. Go to original source... Go to PubMed...
    8. Drici, MD., Burklow, TR., Haridasse, V., Glazer, RI., Woolsey, RL. (1996): Sex hormones prolong QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 94: 1471-1474. Go to original source... Go to PubMed...
    9. Drici, MD., Wang, WX., Liu, XK., Woosley, RL., Flockhart, DA. (1998) Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 18: 477-481. Go to original source... Go to PubMed...
    10. Drolet, B., Khalifa, M., Daleau, P., Hamelin, BA., Turgeon, J. (1998): Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug related lengthening of the QT interval. Circulation 97: 204-210. Go to original source... Go to PubMed...
    11. Gajwani, P., Pozuelo, L., Tesar, GE. (2000): QT interval prolongation associated with quietapine (Seroquel) overdose. Psychosomatics 41: 63-65. Go to original source... Go to PubMed...
    12. Haverkamp, W., Breithardt, G., Camm, AJ., et al. (2000): The potential for QT prolongation and pro-arrhythmia by non-anti-arrhyhtmic drugs: clinical and regulatory implications. Report on a Policy conference of the European Society of Cardiology. Cardiovasc Res 47: 219-233. Go to original source... Go to PubMed...
    13. Jervell, A., Lange-Nielsen, F. (1957): Congenital deaf-mutism, functional heart disease with prolongation of QT interval and sudden death. Am Heart J 54: 59-68. Go to original source... Go to PubMed...
    14. Keating, M., Atkinson, D., Dunn, C., et al. (1991) Linkage of cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science 252: 704-706. Go to original source... Go to PubMed...
    15. Kelly, HG., Kay, JE., Laverty, SG. (1963): Thioridazine HCL (Mellaril): its effect on the electrocardiogram and report of two fatalities with electrocardiographic abnormalities. Can Med Assoc J 89: 546-553. Go to PubMed...
    16. Mehtonen, OP., Aranko, K., Malkonen, L., et al. (1991): A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 84: 58-64. Go to original source... Go to PubMed...
    17. Pokorny, R., Finkel, MJ., Robinson, WT. (1994) Normal volunteers should not be used for bioavailibility or bioequivalence studies of clozapine. Pharm Res 11: 1221. Go to original source... Go to PubMed...
    18. Rampe, D., Murawsky, MK., Grau, J., et al. (1998) The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 286: 788-793. Go to PubMed...
    19. Reilly, JG., Ayis, SA., Ferrier, IN., Jones, SJ., Thomas, SHL. (2000): QTc interval abnormalities and psychotrophic drug therapy in psychiatric patients. Lancet 355: 1048-1052. Go to original source... Go to PubMed...
    20. Romano, C., Gemme, G., Pongiglione, R. (1963) Aritmie rare dell´eta pediatrica. Clin Pediatr (Bologna) 45: 656-683. Go to PubMed...
    21. Suessbrich, H., Schoherr, R., Heinemann, SH., et al. (1997): The inhibitory effect of the antipsychotic drug haloperidole on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 120: 968-974. Go to original source... Go to PubMed...
    22. Šišáková, M., Vlašínová, J., Vojtíšková, M. (2001) Kolísání klidových hodnot QT intervalu u pacientů s mutací KCNQ1 genu. Kardiol Rev 3: 8-10.
    23. US Food and Drug Administration. Memorandum: July 19, 2000 Meeting of the Psychofarmacological Drugs Advisory Committee. June 20, 2000.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.